Follow us on Twitter
twitter icon@FreshPatents


Enzyme Inhibitor patents

      

This page is updated frequently with new Enzyme Inhibitor-related patent applications.




 Urea compounds and their use as enzyme inhibitors patent thumbnailUrea compounds and their use as enzyme inhibitors
Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..

 Pde9 inhibitors with imidazo triazinone backbone patent thumbnailPde9 inhibitors with imidazo triazinone backbone
This invention is directed to compounds, which are pde9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
H. Lundbeck A/s


 Hematopoitetic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure patent thumbnailHematopoitetic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
Methods and compositions comprising hematopoietic growth factor proteins and/or protein analogs thereof and/or combinations thereof and angiotensin converting enzyme inhibitors to treat the acute and long term adverse effects of radiation exposure in subjects who have been or will be exposed to radiation are disclosed.. .
The Medical College Of Wisconsin, Inc.


 Selective chemotherapy treatments and diagnostic methods related thereto patent thumbnailSelective chemotherapy treatments and diagnostic methods related thereto
This disclosure relates to methods of identifying subjects that have an increased likelihood of responding to a combination of a poly (adp) ribose polymerase enzyme inhibitor and a platinum based reagent and optionally other anticancer agents in the course of chemotherapy. In certain embodiments, the disclosure relates to methods of treating cancer comprising administering an effective amount of a poly (adp) ribose polymerase enzyme inhibitor and a platinum based reagent to the subject in need thereof, wherein the subject is in need thereof because measuring a quantity of rna isolated from a cancer cell from the subject indicates an increased quantity of the rna compared to a normal sample, wherein the rna is associated with one or more of the following genes/pseudogenes gls, ubec2, hacl1, msi2, and loc100129585..
Emory University


 Family of pain producing substances and methods to produce novel analgesic drugs patent thumbnailFamily of pain producing substances and methods to produce novel analgesic drugs
A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome p-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject.
Board Of Regents Of The University Of Texas System


 Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof patent thumbnailSulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof
A polygulonic acid sulfate or pharmaceutically acceptable salt thereof, preparation method therefor and use thereof in the preparation of tumor growth and/or metastasis inhibitors are disclosed. The polygulonic acid sulfate or pharmaceutically acceptable salt thereof of the present invention can be used in the preparation of any one or more of tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, heparanase inhibitors, c-met enzyme inhibitors, microtubule polymerization inhibitors, actin-depolymerising factor activity inhibitors and actin-aggregation inhibitors..
Shanghai Institute Of Materia Medica Chinese Academy Of Sciences


 Method and composition for preventing and treating viral infections patent thumbnailMethod and composition for preventing and treating viral infections
A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a helicase atpase inhibitor, a sialidase enzyme inhibitor, and icam-1 inhibitor which each also down regulate the immune response.

 Treatment of viral infections by modulation of host cell metabolic pathways patent thumbnailTreatment of viral infections by modulation of host cell metabolic pathways
Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation.
The Trustees Of Princeton University


 Aminoester derivatives patent thumbnailAminoester derivatives
Compounds of formula (i) defined herein are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for treating diseases of the respiratrory tract.. .
Chiesi Farmaceutici S.p.a.


 Aminoester derivatives patent thumbnailAminoester derivatives
Compounds of formula (i) defined herein are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for treating diseases of the respiratory tract.. .
Chiesi Farmaceutici S.p.a.


Bicyclic heterocyclyl derivates as irak4 inhibitors

The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (i), which are therapeutically useful as kinase inhibitors, particularly irak4 inhibitors, wherein a, y, z, x1, x2, r1, r3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly irak4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (i) together with a pharmaceutically acceptable carrier, diluent or excipient therefor..
Aurigene Discovery Technologies Limited

Aminoester derivatives

Compounds of formula (i) are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.. .
Chiesi Farmaceutici S.p.a.

Quinoline derivatives as pde10a enzyme inhibitors

The present invention provides quinoline derivatives of formula i that are pde10a enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for pde10a over other pde subtypes.
H. Lundbeck A/s

Cancer markers and methods of use thereof

The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid ssea-3/ssea-4/globoh in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4galt; beta-4galnact-i; or beta-3galt-v enzymes in the globoseries synthetic pathway.
Academia Sinica

Herbicide-tolerant plants

The present invention provides herbicide-tolerant plants. The present invention also provides methods for controlling the growth of weeds by applying an herbicide to which herbicide-tolerant plants of the invention are tolerant.
Basf Agrochemical Products, B.v.

Herbicide-tolerant plants

The present invention provides herbicide-tolerant plants. The present invention also provides methods for controlling the growth of weeds by applying an herbicide to which herbicide-tolerant plants of the invention are tolerant.
Basf Agrochemical Products, B.v.

Herbicide-tolerant plants

The present invention provides herbicide-tolerant plants. The present invention also provides methods for controlling the growth of weeds by applying an herbicide to which herbicide-tolerant plants of the invention are tolerant.
Basf Agrochemical Products, B.v.

Methods of treating cancer using compositions comprising perillyl alcohol derivative

A method for treating brain metastases of a cancer in a mammal includes administering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate, such as tmz−poh. The brain metastases can be originated or spread from breast cancer.
Neonc Technologies Inc.

Breast cancer cell growth-inhibiting enzyme inhibitors, the production thereof, and use thereof

Novel enzyme inhibitors for treatment of breast cancer combine the inhibition of enzymes that combat aggressive breast cell growth both synergistically and additively. Pyrido-annulated indoles developed act in a selectively inhibiting manner on the enzymes her2 and/or brk in the nanomolar to picomolar concentration range in screening more than 200 kinases of the human kinome.
Martin-luther-universitÄt Halle-wittenberg

Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug..
Signature Therapeutics, Inc.

Thermoplastic article with odor control system

Disclosed is an article for urine odor control. The article may be in the form of a film the article is a homogeneous material may include a water-soluble polymer having an extrusion temperature of 50 to 150 c, and between 0.1% to 50% by weight of an odor-control system.
Kimberly-clark Worldwide, Inc.

A bacterial surrogate for testing of antimalarials: thya knockout, fola knockout, folp knockout, and folk knockout bacteria for testing of inhibition of antifolate pathway

In this invention, cell lines are created for enzyme inhibitory testing of inhibitors against plasmodium falciparum dhfr-ts and hppk-dhps. Provided the complementing dhfr-ts and hppk-dhps have sufficient activities to support growth of the surrogates in un-supplemented medium, the same surrogates could be used for screening inhibitors of targets against other parasite and pathogen species e.g.
National Science And Technology Development Agency

Metalloenzyme inhibitor compounds

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.. .
Viamet Pharmaceuticals, Inc.

Novel glycan conjugates and methods of use thereof

The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the ssea3/ssea4/globoh associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis.
Academia Sinica

Pde9 inhibitors with imidazo triazinone backbone

This invention is directed to compounds, which are pde9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
H. Lundbeck A/s

Urea compounds and their use as faah enzyme inhibitors

Wherein: r1 is selected from hydrogen, halogen, hydroxyl and c1-4 alkoxy; r2 is selected from hydrogen, halogen, hydroxyl and c1-4 alkoxy; r3 is c1-4 alkyl; r4 is aryl which is substituted with a group selected from oso2nh2, nhconh2, nhso2nh2, nhso2c1-4 alkyl and conh2; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; provided that the compound is not n-(1-benzylpiperidin-4-yl)-n-methyl-4-(4-(sulfamoylamino)phenyl)-1h-imidazole-1-carboxamide or n-(1-benzylpiperidin-4-yl)-n-methyl-4-(3-(methyl sulfonamido)phenyl)-1h-imidazole-1-carboxamide. The compound may be used as an inhibitor of fatty acid amide hydrolase..

Method of increasing production of amorpha-4,11-diene and increasing production of natural rubber

The present invention provides a method of increasing production of amorpha-4,11-diene and a method of increasing production of natural rubber. The present invention relates to a method of increasing production of amorpha-4,11-diene which includes the step of attaching an enzyme inhibitor to arabidopsis thaliana into which has been introduced a gene encoding amorphadiene synthase.
Osaka University

Metalloenzyme inhibitor compounds

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.. .
Viamet Pharmaceuticals, Inc.

Multi-functional composition and preparation method and application thereof

A multi-functional composition is disclosed as well as the preparation method and applications thereof. The composition contains a marine algae-derived material and an enzyme inhibitor.
Beijing Bailening Biotechnology Co. Ltd.

New therapeutic uses of enzyme inhibitors

The invention relates to use of compounds which inhibit vap-1/ssao activity for the treatment of muscular dystrophy.. .
Proximagen Limited

Herbicide-tolerant plants

The present invention provides herbicide-tolerant plants. The present invention also provides methods for controlling the growth of weeds by applying an herbicide to which herbicide-tolerant plants of the invention are tolerant.

Therapeutic uses of enzyme inhibitors

The invention relates to use of compounds which inhibit vap-1/ssao activity for the treatment of muscular dystrophy. The invention also relates to combined preparations comprising compounds which inhibit vap-1/ssao activity, and their use for the treatment of muscular dystrophy..

Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents

Disclosed are methods for the treatment of various solid tumors in patients in need of such treatment. The methods comprise administering to such a patient an nedd8-activating enzyme (nae) inhibitor such as (1s,2s,4r)-4-4-(1s)-2,3-dihydro 1h-inden-1-ylamino)-7h-pyrrolo[2,3-d]-pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (mln4924) or a pharmaceutically acceptable salt in combination with one or more chemotherapeutic agents.
Millennium Pharmaceutcals, Inc.

Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ros1 kinase enzyme activity inhibitory effect and ntrk kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (i) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound.
Daiichi Sankyo Company, Limited

Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor

During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or als.

Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor

During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or als.

Arginase inhibitors and methods of use thereof

The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.. .
Astrazeneca Ab

Treatment and prophylaxis of kidney diseases

A method for treatment and/or prophylaxis of kidney diseases of non-inflammatory etiology in mammals is described herein. The method comprises administering hydroxychloroquine, its enantiomer or a pharmaceutically acceptable salt thereof or its combinations with at least one drug selected from the group of angiotensin receptor blockers and angiotensin converting enzyme inhibitors.
Ipca Laboratories Limited

Compositions, methods, and kits for amplifying nucleic acids

The present teachings are directed to compositions, methods, and kits for amplifying target nucleic acids while reducing non-specific fluorescence and undesired amplification products, sometimes referred to as secondary amplification products or spurious side-products. The enzyme inhibitors disclosed herein comprise a nucleotide sequence and at least one quencher.
Applied Biosystems, Llc

Combination therapy with glutaminase inhibitors

The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an anticancer agent such as an enzyme inhibitor (such as a kinase inhibitor), a mitotic inhibitor, a dna-modifying agent, or a cytidine analog. The invention further relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases that are resistant to one or more anticancer agents..
Calithera Biosciences, Inc.

Combinations of oral medicaments bonded by a wrapping

An oral pharmaceutical dosage form is provided which contains at least two medicaments, in which form the medicaments on the one hand are brought together in a leakproof and in-vivo water soluble wrapping and on the other hand are separated so that the active principle of the combined medicaments cannot come into contact with one another. At least one of the medicaments can be chosen from the following therapeutic classes: non-steroidal anti-inflammatory drug (nsaid), proton pump inhibitor (ppi), beta-blocker, statin, conversion enzyme inhibitor (cei), biguanide, myorelaxant, calcium inhibitor, corticoid, antidepressant, benzodiazepine, non-atropine-like intestinal transit retarder, intestinal antibacterial, and the following therapeutic molecules: spironolactone, propranolol, clarithromycin, amoxycillin, low-dose acetylsalicylic acid, potassium, and clopidogrel..
Duo-ge

Quinoline derivatives as pde10a enzyme inhibitors

The present invention provides quinoline derivatives of formula i that are pde10a enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for pde10 over other pde subtypes.
H. Lundbeck A/s

Products and methods using soy peptides to lower total and ldl cholesterol levels

Controlled studies demonstrate that products and related methods using soy related peptides lower total and ldl cholesterol levels in individuals. In one exemplary embodiment of the present disclosure, a product containing an effective amount of lunasin peptides that lowers cholesterol levels in an individual that consumes the lunasin peptides is provided.
Soy Labs, Llc

Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an nae inhibitor or a pharmaceutically acceptable salt thereof, such as ((1s,2s,4r)-4-(4-((1s)-2,3-dihydro-1h-inden-1-ylamino)-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (mln4924) or {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-chloro-2-methoxy-2,3-dihydro-1h-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl)methyl sulfamate (i-216), and a hypomethylating agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine.
Millennium Pharmaceuticals, Inc.

Metalloenzyme inhibitor compounds

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.. .
Viamet Pharmaceuticals, Inc.

Aminoester derivatives

Compounds of formula (i), defined herein, are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract.. .
Chiesi Farmaceutici S.p.a.

Carbamate derivatives

Compounds of formula (i) defined herein are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract.. .
Chiesi Farmaceutici S.p.a.

Advanced auger and filtration system for the saccharification of biomass

The present disclosure provides methods and systems for generating sugars from biomass. The methods and systems provide increased yields of carbohydrates and fermentable sugars by combining enzyme recycling with removal of saccharification enzyme inhibitors and increased solids loading..
Edeniq, Inc.

Pyridazinones as daao enzyme inhibitors

Wherein r1 and r2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.. .

Hbv rnase h purification and enzyme inhibitors

Provided herein are methods for the obtention of an active hbv rnaseh preparation and its use in screening methods to identify potential inhibitors of the enzyme for possible use as therapeutic agents. Also provided are methods of treatment using agents identified according to the screen..
Saint Louis University

Enzyme inhibitors

Wherein each of x, y, r1, r2, r3, r4, and n are as defined herein. Compounds of formula (i) may act as inhibitors of the thioredoxin reductase enzyme system.



Enzyme Inhibitor topics:
  • Enzyme Inhibitor
  • Angiotensin
  • Angiotensin Converting Enzyme
  • Therapeutical
  • Psychiatric
  • Modulation
  • Adventitia
  • Renal Hypertension
  • Renal Artery
  • Hypertension
  • Neurotoxic
  • Hyperactivity
  • Angiotensin Ii
  • Aldosterone
  • Cardiovascular


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Enzyme Inhibitor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Enzyme Inhibitor with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.3695

    file did exist - 2649

    1 - 1 - 51